PHATHOM PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $6.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $6.71M, a 18.86% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $5.53M, a 0.11% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $9.30M, a 64.99% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $8.27M, a 35.63% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $28.72M, a 19.43% increase from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $24.05M, a 46.59% decline from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $45.02M, a 86.57% increase from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $24.13M, a 43.55% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.71M 10-Q · filed 2026-07-30 | $12.25M derived: sum of 2 quarters · filed 2026-07-30 | ||
| 2026-03-31 | $5.53M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $28.72M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $9.30M 10-Q · filed 2025-10-30 | $17.57M derived: sum of 2 quarters · filed 2026-07-30 | $23.11M derived: sum of 3 quarters · filed 2026-07-30 | |
| 2025-06-30 | $8.27M 10-Q · filed 2026-07-30 | $13.81M derived: sum of 2 quarters · filed 2026-07-30 | ||
| 2025-03-31 | $5.54M 10-Q · filed 2026-07-30 | |||
| 2024-12-31 | $24.05M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $5.63M 10-Q · filed 2025-10-30 | $11.73M derived: sum of 2 quarters · filed 2025-10-30 | $17.36M derived: sum of 3 quarters · filed 2025-10-30 | |
| 2024-06-30 | $6.10M 10-Q · filed 2025-10-30 | $11.72M derived: sum of 2 quarters · filed 2025-10-30 | ||
| 2024-03-31 | $5.63M 10-Q · filed 2025-10-30 | |||
| 2023-12-31 | $45.02M 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $6.14M 10-Q · filed 2024-11-07 | $13.39M derived: sum of 2 quarters · filed 2024-11-07 | $20.44M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $7.25M 10-Q · filed 2024-11-07 | $14.30M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $7.05M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $24.13M 10-K/A · filed 2024-06-14 | |||
| 2022-09-30 | $5.82M 10-Q · filed 2023-11-09 | $11.70M derived: sum of 2 quarters · filed 2023-11-09 | $17.48M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $5.88M 10-Q · filed 2023-11-09 | $11.66M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $5.78M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $16.81M 10-K · filed 2023-02-28 | |||
| 2021-09-30 | $4.42M 10-Q/A · filed 2022-11-09 | $8.66M derived: sum of 2 quarters · filed 2022-11-09 | $12.47M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $4.24M 10-Q/A · filed 2022-11-09 | $8.05M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $3.82M 10-Q/A · filed 2022-11-09 | |||
| 2020-12-31 | $5.84M 10-K · filed 2022-03-01 | |||
| 2020-09-30 | $2.07M 10-Q · filed 2021-11-08 | $2.90M derived: sum of 2 quarters · filed 2021-11-08 | $3.46M derived: sum of 3 quarters · filed 2021-11-08 | |
| 2020-06-30 | $828.00K 10-Q · filed 2021-11-08 | $1.39M derived: sum of 2 quarters · filed 2021-11-08 | ||
| 2020-03-31 | $563.00K 10-Q · filed 2021-11-08 | |||
| 2019-12-31 | $406.00K 10-K · filed 2021-03-30 | |||
| 2019-09-30 | $36.00K 10-Q · filed 2020-11-10 | $65.00K derived: sum of 2 quarters · filed 2020-11-10 | ||
| 2019-06-30 | $29.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |